AR073706A1 - Inhibidores del virus de la hepatitis c - Google Patents

Inhibidores del virus de la hepatitis c

Info

Publication number
AR073706A1
AR073706A1 ARP090103750A ARP090103750A AR073706A1 AR 073706 A1 AR073706 A1 AR 073706A1 AR P090103750 A ARP090103750 A AR P090103750A AR P090103750 A ARP090103750 A AR P090103750A AR 073706 A1 AR073706 A1 AR 073706A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
haloalkyl
hydrogen
alkoxy
Prior art date
Application number
ARP090103750A
Other languages
English (en)
Inventor
Sheldon Hiebert
Ramkumar Rajamani
Paul Michael Scola
Michael S Bowsher
Rongti Li
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR073706A1 publication Critical patent/AR073706A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

También se describen composiciones que comprenden los compuestos y procedimientos para usar los compuestos para inhibir el VHC. Reivindicacion 1: Un compuesto caracterizado porque tiene la de formula (1), o una sal farmacéuticamente aceptable del mismo, en la que: n es 0, 1, 2 o 3; R1 se selecciona entre hidrogeno y -NHSO2R6; R2 se selecciona entre hidrogeno, alquenilo, alquilo y cicloalquilo, en la que el alquenilo, el alquilo y el cicloalquilo están cada uno opcionalmente sustituidos con uno, dos, tres o cuatro grupos halo; R3 se selecciona entre hidrogeno, alcoxi, alcoxialcoxi, alquilsulfanilo, alquilosulfonilo, alquilsulfoxilo, hidroxi y (NRcRd)carboniloxi; cada R4 se selecciona independientemente entre alcoxi, alquilo, ciano, dialquilamino, halo, haloalquilo, haloalcoxi, un heterociclo monocíclico, hidroxi y fenilo. donde cada uno del heterociclo monocíclico y el fenilo está opcionalmente sustituido con uno, dos, tres, cuatro o cinco sustituyentes, seleccionados independientemente entre alcoxi, alquilo, dialquilamino, halo, haloalcoxi y haloalquilo; R5 se selecciona entre hidrogeno, alquenilo, alquilo, arilo, arilalquilo, cicloalquilo, (cicloalquil)alquilo, heterociclilo y heterociclilalquilo, donde cada uno del alquilo y el cicloalquilo está opcionalmente sustituido con un grupo seleccionado entre alcoxi, haloalcoxi, halo, haloalquilo, ciano y dialquilamino; R6 se selecciona entre alquilo, arilo, aralquilo, cicloalquilo, (cicloalquil)alquilo, heterociclilo y -NraRb, donde cada uno del alquilo y el cicloalquilo está opcionalmente sustituido con un grupo seleccionado entre alquilo, alcoxi, halo, haloalquilo, ciano, cianoalquilo y haloalcoxi; Ra y Rb se seleccionan independientemente entre hidrogeno, alcoxi, alquilo, arilo, arilalquilo, cicloalquilo, (cicloalquil)alquilo, haloalquilo, heterociclilo y heterociclilalquilo; Rc y Rd se seleccionan independientemente entre hidrogeno y alquilo; Q es una cadena C4-8 saturada o insaturada, estando la cadena opcionalmente sustituida con uno, dos, tres o cuatro grupos seleccionados independientemente entre alquilo, halo y haloalquilo, donde los grupos alquilo o haloalquilo pueden formar opcionalmente un anillo de 3 a 7 miembros con el átomo de carbono al que están unidos; y Z se selecciona entre CH2, O y NRZ; donde Rz se selecciona entre hidrogeno y alquilo.
ARP090103750A 2008-09-29 2009-09-29 Inhibidores del virus de la hepatitis c AR073706A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10090708P 2008-09-29 2008-09-29
US12/559,179 US20100080770A1 (en) 2008-09-29 2009-09-14 Hepatitis C Virus Inhibitors

Publications (1)

Publication Number Publication Date
AR073706A1 true AR073706A1 (es) 2010-11-24

Family

ID=42057725

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103750A AR073706A1 (es) 2008-09-29 2009-09-29 Inhibidores del virus de la hepatitis c

Country Status (7)

Country Link
US (1) US20100080770A1 (es)
EP (1) EP2331552B1 (es)
JP (1) JP2012504126A (es)
CN (1) CN102227435A (es)
AR (1) AR073706A1 (es)
TW (1) TW201018477A (es)
WO (1) WO2010036551A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201071034A1 (ru) * 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5639155B2 (ja) 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
EA201290128A1 (ru) * 2009-09-28 2013-01-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликации вируса гепатита с
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
DK2909205T3 (en) 2012-10-19 2017-03-06 Bristol Myers Squibb Co 9-METHYL-SUBSTITUTED HEXADECAHYDROCYCLOPROPA (E) PYRROL (1,2-A) (1,4) DIAZOCYCLOPENTADECINYLCARBAMATE DERIVATIVES AS NON-STRUCTURAL 3 (NS3) PROTEASE INHIBITORS FOR TREATMENT
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN109020820B (zh) * 2017-06-08 2021-06-25 杭州惠诺医药科技有限公司 一种6-溴-2-氨基萘的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) * 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
JP4654239B2 (ja) * 2004-03-15 2011-03-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウィルス感染症の治療に適した大環状ジペプチドの調製方法
CA2606195C (en) * 2005-05-02 2015-03-31 Merck And Co., Inc. Hcv ns3 protease inhibitors
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
CN101228181B (zh) * 2005-07-20 2013-09-18 默沙东公司 Hcv ns3蛋白酶抑制剂
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
US8268776B2 (en) * 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US8138164B2 (en) * 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2008057208A2 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
MY164469A (en) * 2006-10-27 2017-12-15 Msd Italia Srl Hcv ns3 protease inhibitors
US20080279821A1 (en) * 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
EP2331552B1 (en) 2013-02-27
US20100080770A1 (en) 2010-04-01
JP2012504126A (ja) 2012-02-16
EP2331552A1 (en) 2011-06-15
TW201018477A (en) 2010-05-16
CN102227435A (zh) 2011-10-26
WO2010036551A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
AR073706A1 (es) Inhibidores del virus de la hepatitis c
AR078976A1 (es) Inhibidores heterociclicos de la proteina ns5a codificada por el virus de la hepatitis c(vhc), composiciones farmaceuticas que los comprenden y uso de los mismos para tratar infecciones por vhc
AR079634A1 (es) Inhibidores del virus de la hepatitis c
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
AR063653A1 (es) Inhibidores del virus de la hepatitis c
CO6180424A2 (es) Inhibodores espiro cetona de acetil-coa carboxilasa
AR086290A1 (es) Inhibidores del virus de la hepatitis c
CY1114509T1 (el) Αναστολεις της ns5a toy hcv
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR086934A1 (es) Inhibidores del virus de la hepatitis c
AR073774A1 (es) Compuestos antibioticos oxazolidinona triciclicos
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR091279A1 (es) Inhibidores macrociclicos de virus flaviviridae
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
NZ593806A (en) Inhibitors of hcv ns5a
EA200900697A1 (ru) Ингибиторы вируса гепатита с
CO5611128A2 (es) Compuestos derivados de n-aril-2-oxazolidinona-5-carboxamida como agentes antibacteriales
AR054799A1 (es) Derivados de oxindol
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
AR069740A1 (es) Compuestos nucleosidos antivirales
AR059901A1 (es) Compuestos de tetrahidropiridotienopirimidina utiles para tratar o prevenir trastornos proliferativos celulares.
AR082619A1 (es) Inhibidores del virus de la hepatitis c

Legal Events

Date Code Title Description
FA Abandonment or withdrawal